Patient Home Monitoring (PHM) (TSX VENTURE:PHM), a company focused on in-home
cardiology healthcare services, today announced unaudited results for its third
fiscal quarter ended June 30, 2012. 


PHM will post a webcast on Tuesday, August 28, 2012. This webcast will review
and discuss the third fiscal quarter of 2012 and provide details of the future
growth plans for the company. 


To listen, please visit the investor website at: 

http://www.phmhometesting.com/2012Q3



Q3 2012 Highlights                                                          

--  Generated adjusted EBITDA before patient acquisition costs(2) of
    $283,042. 
--  Generated positive Adjusted EBITDA of $28,489.(2) 
--  Finished integrated platform for management of clinical operations. 
--  Rolled out a state-of-the-art software application for linking in-home
    data, the specialized call center, and clinic locations. 
--  Launched the National Dosing Support Center. 
--  Finalized assessment of additional in-home services suitable for its
    cardiology market patients to expand its offering into underserved large
    markets. 
--  Increased quarterly INR tests(1) recorded to 26,214 from 10,460 the same
    quarter a year ago, a 151% increase over Q3 FY11. 
--  For the last month in the quarter, June 2012, PHM recorded 8,632 INR
    tests. 
--  Increased quarterly revenue to $1,066,153 from $441,997 in Q3 FY 11, a
    141% increase. 
--  Achieved quarterly gross margin of 68.7%, up from 62.4% in Q3 FY 11, a
    10% increase, in the face of an 11% reimbursement cut from Medicare in
    2012. 
--  Increased quarterly gross profit to $732,786 from $275,809 the same
    quarter a year ago, a 165% increase over Q3 FY11. 



For complete financial results, please see PHM's filings at www.sedar.com.

(1) International normalized ratio ("INR") tests and number of cardiology groups
with patients testing are used as measures of current and future sales
performance. Please refer to the "Non-IFRS Measures" section of PHM's MD&A for
further discussion on these operational measures.


(2) Adjusted EBITDA before patient acquisition costs and Adjusted EBITDA. In
calculating Adjusted EBITDA before patient acquisition costs certain items are
excluded from net loss including interest, taxes, amortization, non-cash
stock-based compensation and patient acquisition costs. In calculating Adjusted
EBITDA certain items are excluded from net loss including interest, taxes,
amortization and non-cash stock-based compensation. Please refer to the
"Non-IFRS Measures" section of PHM's MD&A for further discussion on these
operational measures at

http://phmhometesting.com/investor/public/dl/2012_Q3_MD&A.pdf.

About PHM 

PHM is a healthcare services company focused on providing home-based monitoring
services and supplies for cardiology patients. PHM's entry-point service
monitors patients on blood thinner medications such as Coumadin(r) or warfarin.
Medicare recently expanded reimbursement for this in-home service. PHM has a
unique value proposition to cardiology groups that manage patients on blood
thinners, focusing on systemization to enroll patients in PST. This unique,
systemized approach creates an opportunity for physician groups to operate more
efficiently, increasing revenue to their clinic while providing a higher
standard of care for patients. PHM plans to lever its position as a value- added
service provider to expand into other home-based services for these patients and
their referring physicians.


Information in this news release that is not current or historical factual
information may constitute forward-looking information within the meaning of
securities laws. Implicit in this information, particularly in respect of the
future outlook of PHM and anticipated events or results, are assumptions based
on beliefs of PHM's senior management as well as information currently available
to it. While these assumptions were considered reasonable by PHM at the time of
preparation, they may prove to be incorrect. Readers are cautioned that actual
results are subject to a number of risks and uncertainties, including the
availability of funds and resources to pursue operations, decline of
reimbursement rates, dependence on few payors, possible new drug discoveries, a
novel business model, dependence on key suppliers, granting of permits and
licenses in a highly regulated business, competition, low profit market segments
as well as general economic, market and business conditions, and could differ
materially from what is currently expected.
(TSXV:INR)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Charts.
(TSXV:INR)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Charts.